Beneficial anti-inflammatory effect of paeonol self-microemulsion-loaded colon-specific capsules on experimental ulcerative colitis rats

Zong, Shiyu; Pu, Yang; Li, Suyun; Xu, Benliang; Zhang, Yong; Zhang, Tong; Bing, Wang

doi:10.1080/21691401.2017.1423497

Cited by 22 publications

(9 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-eight male Wistar rats weighing 200 + 20 g were randomly set in six groups of eight rats each. The rats were acclimatized to the animal house conditions (12-h lighting cycle and 25 + 2 C temperature) for 1 week and then arranged as normal control, paeonol control (200 mg/kg orally), 16 ulcer model IND (50 mg/kg orally) 15 -treated, IND/paeonol (50 mg/kg orally) 12 -treated, IND/paeonol (200 mg/kg orally)-treated, and positive control ranitidine (50 mg/kg orally) 17 -treated groups. Both paeonol and ranitidine were administered once daily for 3 days before ulcer induction.…”

Section: Animals and Experimental Proceduresmentioning

confidence: 99%

Mechanisms underlying gastroprotective effect of paeonol against indomethacin-induced ulcer in rats

et al. 2018

View full text Add to dashboard Cite

Paeonol, a natural phenolic compound, possesses diverse beneficial effects including antioxidant and anti-inflammatory effects. Gastric ulcer is still the most prevalent irritant illness among the gastrointestinal diseases. The present study explored the protective effect of paeonol at two dose levels in indomethacin (IND)-induced gastric ulcer in rats. Forty-eight male Wistar rats were arranged into six groups: control, paeonol-treated, IND-treated, IND/paeonol (low and high doses)-treated, and ranitidine-treated groups. The oxidative status was evaluated by determining malondialdehyde level, superoxide dismutase activity, reduced glutathione content as well as hemoxygenase-1 (HO-1) gene expressions, and the antioxidant protein; NAD(P)H quinone oxidoreductase 1 (NQO1) immunostaining. The pro-inflammatory genes nuclear factor κB (NF-κB) and interleukin 1β (IL-1β) were estimated together with the proapoptotic gene of caspase 3. IND caused multiple gastric ulcers with evident oxidative damage and elevated pro-inflammatory and proapoptotic markers. Paeonol protected significantly, in a dose-dependent manner, the gastric mucosa from ulcerative lesion of IND similar to the reference drug ranitidine. Paeonol pretreatment diminished gastric oxidative stress and restored the gastric antioxidant capacity by elevating gastric gene expression of HO-1 and protein expression of NQO1. Paeonol also reduced NF-κB, IL-1β, and caspase 3 gene expressions. In conclusion, paeonol offered a gastroprotection dependent on its antioxidant, anti-inflammatory, and antiapoptotic effects.

show abstract

Section: Animals and Experimental Proceduresmentioning

confidence: 99%

Mechanisms underlying gastroprotective effect of paeonol against indomethacin-induced ulcer in rats

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Moreover, we prepared the colon-specific delivery system (Pae-SME-CSC) with paeonol-loaded self-microemulsion (Pae-SMEDDS), and evaluated its properties in vitro and in vivo, especially the anti-inflammatory effects on UC rats. It indicated that the developed Pae-SME-CSC was suitable for colon-specific drug delivery [ 70 ].…”

Section: Pharmaceutical Strategiesmentioning

confidence: 99%

Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease

Guo

Zong

et al. 2018

Molecules

Self Cite

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a common disease characterized by chronic inflammation in gastrointestinal tracts, which is primarily treated by administering anti-inflammatory and immunosuppressive drugs that inhibit the burden of intestinal inflammation and improve disease-related symptoms. However, the established therapeutic strategy has limited therapeutic efficacy and adverse drug reactions. Therefore, new disease-targeting drug-delivery strategies to develop more effective treatments are urgent. This review provides an overview of the drug-targeting strategies that can be used to treat IBD, and our recent attempts on the colon-specific delivery system (Pae-SME-CSC) with a paeonol-loaded self-microemulsion (Pae-SMEDDS) are introduced.

show abstract

“…Treatment of IBD continue to be challenging despite of advancements in research being carried out. For several years, strategies like development of microspheres [47], liposomes [48], microemulsions [49], nanocores [50], etc. have been adopted for targeted delivery of drug in the treatment of IBD.…”

Section: Histopathological Studiesmentioning

confidence: 99%

Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease

Sinhmar

Shah

Rawal

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

The major challenge for the treatment of inflammatory bowel disease (IBD) is the incompetence to deliver the drug molecule selectively at the site of inflammation. Taking this into consideration, we proposed development of mannosylated nanostructured lipid carrier system (Mn-NLCs) for active targeting and site-specific delivery of budesonide to the inflamed tissues. The developed Mn-NLCs were characterized for particle size and size distribution, zeta potential, %entrapment efficiency, FTIR and TEM analysis. Furthermore, to ensure delivery of developed cargo to the colonic region, the Mn-NLCs were encapsulated using Eudragit S100 coated pellets. The in vivo evaluation of developed system was performed by employing oxazolone colitis rat model. The average particle size of Mn-NLCs (301.7 ± 2.88 nm) was found to be more than that of unconjugated NLCs (284.0 ± 4.53 nm) with marginally reduced % entrapment efficiency (90.88 ± 3.86%). The in vitro cytotoxicity studies using J774A.1 cell line revealed that Mn-NLCs were non-toxic as compared to pure drug. The in vivo evaluation depicted that Mn-NLCs showed significant reduction in clinical activity scoring, macroscopic and microscopic indexing, colonic myeloperoxidase activity and inflammatory cytokines. In conclusion, the developed Mn-NLCs appear to be promising for the treatment of IBD by selectively targeting inflamed colonic region as compared to unconjugated nanoparticulate system.

show abstract

Beneficial anti-inflammatory effect of paeonol self-microemulsion-loaded colon-specific capsules on experimental ulcerative colitis rats

Cited by 22 publications

References 73 publications

Mechanisms underlying gastroprotective effect of paeonol against indomethacin-induced ulcer in rats

Mechanisms underlying gastroprotective effect of paeonol against indomethacin-induced ulcer in rats

Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease

Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease

Contact Info

Product

Resources

About